2+ day, 16+ hour ago   (218+ words) Khartis was co-founded two years ago by the team at XinThera, a biotech acquired by Gilead. Armed with $95m in funding and a former Pfizer drug discovery specialist, Khartis Therapeutics has emerged with the aim of bringing a new treatment for…...

2+ day, 18+ hour ago   (101+ words) Xanadu and University of Alberta to develop quantum algorithms for cancer Pharmaceutical Technology Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to treat cancer. Go deeper with GlobalData The…...

3+ day, 16+ hour ago   (253+ words) Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients. The decision marks the third…...

3+ day, 16+ hour ago   (73+ words) Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration Pharmaceutical Technology Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free…...

3+ day, 16+ hour ago   (514+ words) Recommended changes to the US immunisation schedule by President Trump have been met with widespread retaliation. International health authorities have launched a staunch defence of childhood immunisation, following a recent upheaval in the US that could significantly curb vaccine recommendations…...

4+ day, 16+ hour ago   (402+ words) The 65-year-old kidney transplant patient had developed progressive, multidrug-resistant E. coli malakoplakia, a rare disease characterised by intracellular bacterial persistence, post-transplant. While the patient initially received antibiotics to treat the infection and mass that arose from the bladder wall and prostate,…...

3+ day, 17+ hour ago   (251+ words) The latest round brings the total capital raised by Remepy to $62m. Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s…...

4+ day, 16+ hour ago   (211+ words) Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest of several major industry players, including Regeneron’s venture, which co-led the biotech’s raise with…...

4+ day, 16+ hour ago   (434+ words) The two companies have secured $90m and $152m, respectively, to take their drugs to pivotal development. Two biotech companies, Epicrispr Biotechnologies and Vaderis Therapeutics, have secured fresh capital to take their rare disease assets to late-stage trials – potentially poising these drugs to…...

5+ day, 12+ hour ago   (476+ words) In Association with Cencora Launching a product across Europe’s fragmented healthcare systems presents unique challenges that first-timers are often unprepared for, say experts from Cencora. How can emerging biotechs navigate the risks, accelerate market entry, and prevent launches from derailing?...